14-day Premium Trial Subscription Try For FreeTry Free
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Steris (STE) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.02 per share a year ago.
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 third quart
Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.
STERIS' (STE) Healthcare segment continues to benefit from procedure volume recovery.

STERIS' (STE) Q2 2024 Earnings Call Transcript

01:05pm, Wednesday, 08'th Nov 2023
STERIS plc (NYSE:STE ) Q2 2024 Earnings Conference Call November 8, 2023 9:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations Dan Carestio - President and CEO Mike Tokic
STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE